Taiwan Advance Bio-Pharmaceutical Receivables

The latest receivables for 4186.TWO is $88M as of June 2026. That compares with $92M in the prior-year period — down 4.0% year over year. Investors often review this figure alongside Taiwan Advance Bio-Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4186.TWO's receivables moved from $92M to $88M — a 4.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Taiwan Advance Bio-Pharmaceutical's operating scale or balance-sheet position.

A receivables figure of $88M for 4186.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4186.TWO's receivables ($88M), review year-over-year change from $92M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Taiwan Advance Bio-Pharmaceutical's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.